TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05273879

Intervention type: PROCEDURE
Group type: OTHER
Intervention: decompression
Description: laminotomy of the corresponding adjacent vertebrae, partial flavectomy and medial facetectomy are planned to be performed unilaterally. Depending on the surgeon's personal preferences, the following two options are available: 1) equivalent decompression procedure contralaterally and 2) crossover contralateral decompression. Irrespective of the selected option, the spinous process, the interspinous and supraspinous ligaments, part of the facet joints, and the corresponding part of the vertebral arch must be preserved intact in all participants.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: fusion
Description: First, decompression is performed according to one of the above methods. Next, trans-foraminal interbody fusion with a cage (TLIF) and fixation with pedicle screws are performed.
Study: NCT05492695

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Galcanezumab
Description: Galcanezumab is a calcitonin-gene related peptide antagonist indicated in adults for the preventive treatment of migraine and the treatment of episodic cluster headache.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Galcanezumab' placebo. This is the same vehicle as the study intervention formulation but does not contain active galcanezumab-gnlm.
Study: NCT04680442

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Trastuzumab is a HER-2 targeting monoclonal antibody that improves overall survival and reduces the risk of recurrent disease in early stage HER-2 positive breast cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab is a HER-2 targeting monoclonal antibody that improves overall survival and reduces the risk of recurrent disease in early stage HER-2 positive breast cancer.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pertuzumab
Description: Pertuzumab (also called 2C4, trade name Perjeta) is a monoclonal antibody used in combination with trastuzumab and docetaxel for the treatment of metastatic HER2-positive breast cancer; it also used in the same combination as a neoadjuvant in early HER2-positive breast cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Pertuzumab (also called 2C4, trade name Perjeta) is a monoclonal antibody used in combination with trastuzumab and docetaxel for the treatment of metastatic HER2-positive breast cancer; it also used in the same combination as a neoadjuvant in early HER2-positive breast cancer

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab emtansine
Description: Ado-trastuzumab emtansine is approved to treat: Breast cancer that is HER2 positive and has already been treated with a taxane and trastuzumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine
Description: Ado-trastuzumab emtansine is approved to treat: Breast cancer that is HER2 positive and has already been treated with a taxane and trastuzumab.
Study: NCT06387394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOTOX
Description: Intramuscular Injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOTOX
Description: Intramuscular Injections

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular Injections
Study: NCT06518603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine citrate 20mg/kg/day
Description: Caffeine citrate 20mg/kg/day given orally once daily for 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-Sterile water 1ml/kg/day
Description: Placebo-sterile water 1mg/kg/day given orally once daily for 28 days
Study: NCT04505865

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Reduction
Description: The stress reduction program is a multimodal mind-body resiliency program that incorporates 3 core components into each session:~1) Elicitation of the Relaxation Response through mind-body techniques; 2) discussion about stress awareness to learn how to identify personal stressors and experiences of stress; and 3) coping strategies and adaptive perspective-taking to promote positive well-being.
Study: NCT04174755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide Injectable Product
Description: Semaglutide 0.25 mg subcutaneously once weekly for 4 weeks, then Semaglutide 0.5 mg subcutaneously once weekly for 4 weeks, then Semaglutide 1 mg subcutaneously once weekly for 20 weeks. Total treatment duration 28 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Diet and exercise advice for 40 weeks

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard of care
Description: Diet and exercise advice for 40 weeks
Study: NCT06506266

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HFA-152a
Description: HFA-152a is administered via oral inhalation
Study: NCT04539795

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral tablet
Study: NCT06506266

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HFA-152a
Description: HFA-152a is administered via oral inhalation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HFA-134a
Description: HFA-134a is administered via oral inhalation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HFA-134a
Description: HFA-134a is administered via oral inhalation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiolabeled saline solution
Description: Radiolabeled saline solution is administered via oral inhalation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiolabeled saline solution
Description: Radiolabeled saline solution is administered via oral inhalation
Study: NCT06093815

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Injection
Description: A pre specified amount will be injected in tissue at selected timepoints

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Injection
Description: A pre specified amount will be injected in tissue at selected timepoints
Study: NCT06585488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-53038
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-53038
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-53038
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-53038
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-53038
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: administered by intravenous infusion
Study: NCT05714956

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mothers and Babies Online (eMB)
Description: This study's intervention is called Mothers and Babies Online or eMB, which consists of 8 sessions that correspond with key cognitive-behavioral therapy (CBT) elements: pleasant activities, thoughts, and social support/contact with others. Integrated throughout eMB are activities and skills based on attachment theory that emphasize how each CBT module relates to promoting a strong, nurturing connection between parent and child. eMB includes informational pages, short audio/video clips, images of infants and pregnant women, and worksheets for participants to enter personalized information in response to the lesson content. eMB is individually guided without facilitation, b) clients control the pace by which they review online content, c) and clients can review online content as many times as they like. Participants who receive eMB will also complete assessments at baseline, 1 week post-intervention, and 3 months post-intervention.
Study: NCT06375733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GFH009
Description: administered as an IV infusion at the dose levels 75mg, 60mg, and/or 100mg QW.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: administered at 160mg BID oral; 28-day a cycle until disease progresses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GFH009
Description: the RP2D of GFH009 defined in the preliminary phase 1b trial with the same schedule as in the phase Ib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: administered at 160mg BID oral; 28-day a cycle until disease progresses.
Study: NCT04784715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: Administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: Administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered by intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Taxane
Description: Investigator's choice of docetaxel or paclitaxel administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Administered by intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pertuzumab
Description: Administered by intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Administered by intravenous infusion
Study: NCT05051150

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrin 0.03
Description: epinephrine infusion rate of 0.03 mcg/kg/min will start from subarachnoid injection of local anesthetic until 5-min after baby delivery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrin 0.05
Description: epinephrine infusion rate of 0.05 mcg/kg/min will start from subarachnoid injection of local anesthetic until 5-min after baby delivery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrin 0.07
Description: epinephrine infusion rate of 0.07 mcg/kg/min will start from subarachnoid injection of local anesthetic until 5-min after baby delivery
Study: NCT05018260

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Bias Modification
Description: Feedback according to participants' viewing patterns, in order to modify their attention bias to threat

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Control
Description: Feedback according to participants' viewing patterns, in order to strengthen their attention control
Study: NCT04672265

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mother tongue and Norwegian
Description: The screening invitation letter, the information leaflet, the reminder letter and the result letter will be sent in two languages; an official language in the country where the invitee is born, and Norwegian.
Study: NCT05163470

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: early on filed functional rehabilitation
Description: Intervention 1 ,called ''On FI.RE. framework '' included a on filed functional rehabilitation framework ,with early return of the player on the field activities during injury recovery. Involve a specific 5 stages framework of functional rehabilitation on filed. Criteria of inclusion and exclusion for each stage are included based on pain, oedema and range of motion specific to nature of injury . Additional included a daily session planning framework for on field functional rehabilitation with a content ,duration and the description of each content.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional on filed functional rehabilitation
Description: Intervention 2 ,called 'traditional rehabilitation' include a on field functional rehabilitation framework ,as the late phase of injury recovery .The framework described as a 5 stages on filed rehabilitation framework based on load monitoring usingGlobal positioning system.No criteria for the player to return to activity on the field cited ,but referred criteria for progression in each stage based on Strength/power depending of the nature of injury.
Study: NCT04993794

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XueBiJing Injection
Description: XueBiJing, specification 10mL/ampule, packaging 10 ampules/container, concentration 0.1g/mL, were manufactured by a Good Manufacturing Practice certified company in China (Tianjin Chase Sun Pharmaceutical Co., Tianjin, China; China lot number 1304291, 1401091 and, 1501261). Generally, the treatment duration of the study was at least 5 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Same saline dose as XueBiJing injection is taken intravenously.
Study: NCT05741281

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical exercises program
Description: - Physical exercise program is an innovative exercise program-consisting of three basic parts (warm up - physical fitness - cool down). It was developed previously by the researcher under the supervision of experienced trainer of physical exercise. The session will begin with a 5- to 10-minutes warm-up consisting of stretching and bending movements. This will be followed by physical fitness phase for 30 to 35 minutes which consist of rapid walking accompanied by a variety of arm and leg movements. The session will be ended by a 5- to 10-minutes cool down phase similar to the warm-up. The total time needed for finishing the physical exercise intervention will be approximately 1 hour.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical exercises program
Description: - Physical exercise program is an innovative exercise program-consisting of three basic parts (warm up - physical fitness - cool down). It was developed previously by the researcher under the supervision of experienced trainer of physical exercise. The session will begin with a 5- to 10-minutes warm-up consisting of stretching and bending movements. This will be followed by physical fitness phase for 30 to 35 minutes which consist of rapid walking accompanied by a variety of arm and leg movements. The session will be ended by a 5- to 10-minutes cool down phase similar to the warm-up. The total time needed for finishing the physical exercise intervention will be approximately 1 hour.
Study: NCT05529056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine Sulfate 01
Description: Atropine sulfate 01 ophthalmic solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine Sulfate 02
Description: Atropine sulfate 02 ophthalmic solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine Sulfate 03
Description: Atropine sulfate 03 ophthalmic solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo ophthalmic solution
Study: NCT06442865

Intervention type: DEVICE
Intervention: AMNIODERM+
Description: A common surgical approach in chronic wound treatment aims at the promotion of epithelization by a combination of debridement manipulations (removal of non-vital tissues) and infection/inflammation management using antibacterial wound dressings (antibiotics or silver covering). The advantages of biomaterials can be attributed to their unique mechanical, immunological, and regenerative properties.~The product will be evaluated in the subjects not responding to SoC.

Intervention type: DEVICE
Intervention: AMNIODERM+
Description: A common surgical approach in chronic wound treatment aims at the promotion of epithelization by a combination of debridement manipulations (removal of non-vital tissues) and infection/inflammation management using antibacterial wound dressings (antibiotics or silver covering). The advantages of biomaterials can be attributed to their unique mechanical, immunological, and regenerative properties.~The product will be evaluated in the subjects not responding to SoC.
Study: NCT05100706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Continuous adductor canal block (CACB)
Description: Ropivacaine 0.2% infusion through adductor canal catheter

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sham continuous adductor canal block (ShACB).
Description: NaCl 0.9% infusion through adductor canal catheter
Study: NCT05932342

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated program of cognitive remediation, physical exercise and socially stimulating activity
Description: Cognitive Remediation (CR) is a well-established intervention that aims to improve neurocognitive abilities (such as memory performance, executive functioning, processing speed, and attention) using four techniques: didactic teaching, computerized drills, in-class strategic monitoring and discussions of the generalization of cognitive skills to daily life.~The physical exercise component consists of physical activities designed for the geriatric population that aim to reduce sedentary behaviors while increasing social engagement.~The socially stimulating activity aim to decrease social isolation, improve well-being, community connection and rapport.
Study: NCT06679413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam
Description: Study participants will receive a pre specified single oral dose of probe drug midazolam on Day 1 and Day 22 of the study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Study participants will receive a pre-specified single oral dose of probe drug metformin on Day 1 and Day 22 of the study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupropion
Description: Study participants will receive a pre-specified single oral dose of probe drug bupropion on Day 1 and Day 22 of the study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fenfluramine HCl
Description: Study participants will receive pre-specified repeated oral doses of fenfluramine HCl (ZX008) from Day 6 to 26 during the study
Study: NCT06689618

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The WB-EMS Device is a fitness device that delivers whole-body electrical muscle stimulation in conjunction with exercise programs. After donning a base layer consisting of fitted shorts and shirt, a vest, shorts, and arm straps with integrated electrodes mapped to major muscle groups (biceps, triceps, pectorals, abdominals, periscapular musculature, paraspinal musculature, gluteus musculature, quadriceps, and hamstrings) are donned. The suit connects to an impulse pack that communicates with the Katalyst iPad App to deliver the programmed stimulation to the participant. Within the Katalyst App, there are leveled exercise programs where low levels (i.e. Level 1 and 2) are simple movements and higher levels (i.e. Levels 3, 4, and 5) have more complex and dynamic movements. There is complete user control of the stimulation level of each individual muscle group to tailor to participant responses and tolerance.
Study: NCT06723756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A: BGF MDI HFO
Description: Participants will receive 2 inhalations of BGF MDI HFO (Budesonide/glycopyrronium/fomoterol fumarate pressurized inhalation suspension 160/14.4/4.8 μg per actuation) as a single dose via oral inhalation administered during 1 Treatment period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment B: BGF MDI HFA
Description: Participants will receive 2 inhalations of BGF MDI HFA (Budesonide/glycopyrronium/fomoterol fumarate pressurized inhalation suspension 160/14.4/4.8 μg per actuation) as a single dose via oral inhalation administered during 2 Treatment periods.
Study: NCT06736574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omecamtiv Mecarbil (OM)
Description: Oral Tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Tablet
Study: NCT06734364

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: buddy tape
Description: Buddy-taping a finger dynamically splints one finger to an adjacent, uninjured finger.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: splint
Description: Short arm splint immobilize and maintain stability of the injured finger, the hand is immobilized in the intrinsic plus position with syndactyly of the injured finger and adjacent finger
Study: NCT06735482

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic play program
Description: Therapeutic Play programs include activities that address core strength, bilateral coordination, motor skills, visual skills, body awareness, outdoor sensory activities, vestibular, and balance skills.
Study: NCT06735196

Intervention type: DEVICE
Group type: OTHER
Intervention: sampling capsule endoscopy
Description: Healthy volunteers swallowed SCEs to collect intestinal fluids in different intestinal areas. When SCEs excreted, the fluids inside SCEs would be collected for microbiome and metabolome analysis.